Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04152564
Other study ID # 440
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 29, 2018
Est. completion date September 8, 2022

Study information

Verified date September 2022
Source South Egypt Cancer Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

60 Patients will be randomly assigned using computer generated randomization program (http://www.randomizer.org) into two groups, First group (Control group ,Group of continous epidural infusion [CEI]), where patients will receive continuous epidural infusion of L-bupivacaine 0.125 % at a rate of .1 ml/kg/h during the first 48 hours after surgery. Second group (Group of continous preperitoneal infusion [CPI]), where patients will receive continuous pre-peritoneal wound infusion with L-bupivacaine 0.25% at 10 ml/h during the first 48 hours after surgery.


Description:

All patients will receive IV morphine when needed for a period of 48 hours with a PCA device programmed to deliver 1 mg/dose with a 10-minute lockout time without background infusion. CEI group The epidural catheter will be placed via a paramedian approach as close as possible to the surgical procedure via the inter-vertebral space (from T7 to T10) so that the affected dermatomes of the surgical wound would receive the benefits of bupivacaine infusion. Proper placement of the catheter was verified through an aspiration test and a test dose (2 ml) of lidocaine 2%. At the end of surgery, a 14 ml bolus of L-bupivacaine 0.125 will be administered through the catheter and then a continuous rate of .1 ml/kg/h infusion of L-bupivacaine 0.125 will be delivered. CPI group At the end of surgery and after the closure of the peritoneal layer, the catheter will be allocated above the peritoneum within the musculofascial layer and secured to the skin with an occlusive dressing. Thereafter, a 20 ml bolus of L-bupivacaine 0.25% will be administered through the catheter and then a continuous fixed-rate infusion of L-bupivacaine 0.25% will be delivered. Outcome Measures The primary outcome will be the pulmonary effects including . Respiratory mechanics: Forced Vital Capacity (FVC) &Forced Expiratory Volume in one second (FEV1) will be assessed preoperatively and at 12h, 24h and 48 hours postoperatively. The Secondary outcome of the study will include the following: - Cardiac enzymes: Troponin I and plasma BNP levels will be measured preoperatively and postoperative day 1 and day 2. - Intensity of pain at rest and during pain-provoking movements (deep breathing, coughing, mobilization) measured by VAS pain score immediately postoperative then at 2, 4 ,6 ,12, 24 ,36 &48 hours after surgery. - Hemodynamic variables including (systolic and diastolic BP, heart rate, oxygen saturation & respiratory rate) measured preoperatively (baseline measurement) then immediately postoperative and at 2, 4 ,6 ,12, 24 ,36 &48 hours after surgery. - Blood gases will be drawn preoperatively and at 12 hour interval in the PACU for assessment of Oxygen tension (PO2) & Co2 tension (PCO2). - Morphine titration and dosage required in the post-anesthesia care unit (PACU). - IV PCA Total morphine consumption during first 48 hours postoperatively. - Time of return of intestinal sounds. - CVP will be measured preoperatively and at post anaesthesia care unit for crude assessment of cardiac function - Quality of night sleep assessed at 8:00 am on postoperative days 1 and 2 using a verbal numerical scale (VNS) ranging from 0 (poor quality) to 10 (excellent quality). - Patient satisfaction with the quality of postoperative analgesia 48 hours after the end of surgery, assessed on a 5-point scale (completely dissatisfied, dissatisfied, not satisfied nor dissatisified, satisfied or completely satisfied [34]. - side effects, including hemodynamic variables (hypotension & bradycardia), supine hypotension ,shivering ,bladder distension and PONV. - Complications of Thoracic epidural as (Inadvertent intrathecal injection, Spinal hematoma, Spinal abscess, superficial cellulites, PDPH, Nerve injury &Back pain) will be assessed and managed


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date September 8, 2022
Est. primary completion date July 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Patients subjected to major upper abdominal cancer surgery. - The enrolled age will be from 18 years to 70 years - ASA, I-III and NYHA, I-III. Exclusion Criteria: - ASA physical status and NYHA >III, - pregnant women, - body mass index >40 kg/m2, - preoperative opioid consumption, - Contraindications or patient's refusal of epidural analgesia, and inability to use a PCA device. - Contraindications of use of spirometry device : A) Cerebral aneurysm, Recent brain surgery, recent concussion, recent eye surgery& Significant glaucoma. B) Recent sinus surgery or middle ear surgery or infection. C) Pneumothorax, Significant aortic aneurysm, Recent thoracic surgery or Recent abdominal surgery . D) Systemic hypotension or severe hypertension (eg, >200/120 mmHg), Significant atrial/ ventricular arrhythmia , Noncompensated heart failure , Recent myocardial infarction or pulmonary embolus. E) History of syncope related to forced exhalation/cough. F) Active tuberculosis , Hemoptysis or oral bleeding . 7-Uncooperative patients regarding use of spirometry [Inability to follow directions (eg, confusion, dementia, young age, language barrier)].

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
levo-bupivacaine infusion via Thoracic epidural catheter
The epidural catheter will be placed via a paramedian approach as close as possible to the surgical procedure via the inter-vertebral space (from T7 to T10) so that the affected dermatomes of the surgical wound would receive the benefits of bupivacaine infusion
levo-bupivacaine infusion via preperitoneal catheter
At the end of surgery and after the closure of the peritoneal layer, the catheter will be allocated above the peritoneum within the musculofascial layer and secured to the skin with an occlusive dressing

Locations

Country Name City State
Egypt South Egypt Cancer Inistitute Assiut
Egypt South Egypt Cancer Inistitute Assiut

Sponsors (1)

Lead Sponsor Collaborator
South Egypt Cancer Institute

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Other Morphine titration and dosage required in the post-anesthesia care unit (PACU). IV PCA Total morphine consumption during first 48 hours postoperatively. first 48 hours postoperatively.
Primary change in Respiratory mechanics Forced Vital Capacity (FVC) &Forced Expiratory Volume in one second (FEV1) will be assessed preoperativly and at Day 1 & Day2 postoperative. preoperative-Day 1 & Day2 postoperative
Secondary change in Cardiac enzymes levels Troponin I and plasma BNP levels will be measured preoperatively and postoperative day 1 and day 2. preoperatively and postoperative Day 1 and Day 2.
Secondary change in Visual analogue pain score Intensity of pain at rest and during pain-provoking movements (deep breathing, coughing, mobilization) measured by VAS pain score with 11points where 0 means no pain,10 means sever pain immediately postoperative then at 2 hours, 4hours ,6hours ,12hours, 24hours ,36hours &48 hours after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT03144622 - 18F-FSPG PET/CT Imaging in Patients With Cancers
Completed NCT04553471 - Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers N/A
Completed NCT02566096 - Efficacy of Transverses Abdominis -Plane Block With Bupivacaine Versus Bupivacaine With Morphine Postoperatively Phase 4
Recruiting NCT05533424 - Ultrasound Guided Quadratus Lumborum Block Versus Transversus Abdominis Plane Block as Postoperative Analgesia in Patients Undergoing Abdominal Cancer Surgery. Phase 3
Completed NCT04729634 - Survey Of Mobilisation and Breathing Exercises After Thoracic and Abdominal Surgery N/A
Completed NCT03555266 - NSS-2 BRIDGE Device in Post-Operative Pain Management N/A
Active, not recruiting NCT00493688 - A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Withdrawn NCT04114422 - A Seven-day Preoperative Exercise Training Program in People With Abdominal Cancer N/A
Recruiting NCT04199754 - IV Contrast-Enhanced Cone Beam Computed Tomography (CBCT) in Radiotherapy Early Phase 1
Recruiting NCT03063112 - Radiofrequency and Chemical Neurolysis of Thoracic Splanchnic Nerve for Abdominal Cancer Pain N/A
Completed NCT02998736 - Trial of Perioperative Tadalafil and Influenza Vaccination in Cancer Patients Undergoing Major Surgical Resection of a Primary Abdominal Malignancy Phase 1
Completed NCT00780611 - Investigating the Improvement in 4D CT Images Using AV Biofeedback
Completed NCT00415675 - Respiratory Tumor and Normal Tissue Motion N/A
Not yet recruiting NCT05903430 - A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy (MIDSECTION)
Completed NCT03751384 - Improvement of Compliance for High Doses of EPA Amongst Patients With Colorectal Cancer N/A
Recruiting NCT05219058 - Reconstruction in Extended MArgin Cancer Surgery
Completed NCT03102619 - Wireless Assessment of Respiratory and Circulatory Distress; A Pilot Study N/A
Not yet recruiting NCT06265948 - Comparsion Between Intravenous Infusion of Ketofol and Inhalational Anasthetics in Abdominal Cancer Surgeries for Post Operative Analgesia
Completed NCT05524454 - Evaluation of a Cone-beam CT Scanner for Image Guided Radiotherapy N/A
Completed NCT04316871 - Dosage of Epidural Morphine in Elderly Patients Phase 4